The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice

Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):63-68. doi: 10.31138/mjr.30.1.63. eCollection 2019 Jun.

Authors

Evrydiki Kravvariti¹, George D Kitas^{2

3}, Petros P Sfikakis¹

Affiliations

¹ First Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, National & Kapodistrian University of Athens Medical School, Athens, Greece.
² Clinical Research Unit, Dudley Group NHS Foundation Trust, Dudley, UK.
³ Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK.

No abstract available

Keywords: Nocebo; biosimilars; drug discontinuation; nocebo effect; rheumatoid arthritis.

Publication types

Review